⚕ GalenOps CRO console
← SITE015 (POL)

SITE015-0184

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE015 (POL) (Dr. Ito) · consented 2022-10-06
Adverse events
9
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-10-21 (study day 3); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 43); relationship: N

moderate assessed 2026-08-18

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-25 (study day 68); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 70); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-16 (study day 90); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 130); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-22 (study day 155); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-04-15 (study day 179); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-04-20 (study day 184); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.